linjc16/ctgov huggingface dataset:
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.

Detailed Description
-----------------
In a multi-center pragmatic clinical trial, COVID-19 positive patients admitted to 6 United States medical centers were enrolled between March 10 and June 4, 2020. A machine learning algorithm was used to determine which patients were suitable for treatment with hydroxychloroquine.

Official Title
-----------------
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial

Conditions
-----------------
COVID-19, Coronavirus, Mortality

Intervention / Treatment
-----------------
* Device: COViage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient admitted to covered ward and tested positive for COVID-19 Patient had COViage applied to electronic health record data within four hours of COVID-19 test Exclusion Criteria: Patient not admitted to covered ward or tested negative for COVID-19 Patient had COViage applied to electronic health record data greater than four hours after COVID-19 test
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exposed group<br>All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers. | Device: COViage<br>* Machine learning intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality outcome | Time to in-hospital death | Through study completion, an average of 3 months |
Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to identify biological data linked to auto immune abnormalities associated with Down Syndrome.

Official Title
-----------------
Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome

Conditions
-----------------
Down Syndrome With and Without Auto Immune Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Free and complete trisomy 21 aged between 8 and 36 years biological or clinical signs of auto-immune disorder (group 1) no sign of auto-immune disorder (group 2) Exclusion Criteria: any antimitotic or immune depressing treatment during the last 6 months Current infectious disease Corticosteroid therapy in the last 3 weeks pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| with abnormalities<br>Down syndrome patients presenting with at least one sign of auto immune abnormality | |
| without abnormality<br>Down syndrome patients without any sign of recognized auto immune condition | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Auto-antibodies dosage |  | at enrolment | 
| specific lymphocytes populations count |  | at enrolment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Down syndrome, Humans,Clinical study,Immunity, Autoimmunity,
Follow up and Observation of Charcot Marie Tooth Disease in Families

Study Overview
=================
Brief Summary
-----------------
The study is aimed to test the hypothesis that there is anticipation in CMT

Official Title
-----------------
Clinical and Genetic Features of Familial Neuropathy

Conditions
-----------------
Charcot-Marie-Tooth Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Patients with Genetically confirmed CMT 1a disease - Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
familial peripheral Neuropathy Anticipation
Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD)

Study Overview
=================
Brief Summary
-----------------
To identify genes causing hypertensive end-stage renal disease (H-ESRD) in high risk African-American populations

Detailed Description
-----------------
BACKGROUND: Although hypertension is a predisposing factor for end stage renal disease, the underlying hypothesis of this study was that in select African-American families genetic factors predisposed them to develop ESRD in the face of hypertension. An inherited basis for H-ESRD was supported by familial clustering of H-ESRD among African Americans that could not be explained by socioeconomic status, access to medical care, and the prevalence of diabetes and hypertension. DESIGN NARRATIVE: DNA samples were collected, identified, and clinically characterized from African-American sib-pairs (and other family members with hypertensive end-stage renal disease). This aspect of the study was based on the fact that Dr. Freedman, the principal investigator, had already developed a unique family history of end-stage renal disease database independently funded by the End-Stage Renal Disease Network Six. This registry served as a very large and unique collection of African-American end-stage renal disease patients. He began with a candidate gene approach for linkage to hypertensive end-stage renal disease in his patient samples using a variety of growth factor genes, genes involved in sodium transport and vascular tone, as well as human homologues of rodent genes that had, or were to be identified in the future as contributing to ESRD in that organism. If this initial first pass of candidate genes failed to demonstrate linkage to hypertensive end-stage renal disease, a systematic genome-wide scan was to be performed with available simple sequence length polymorphisms (SSLP) and other polymorphic markers. Hypertensive end-stage renal disease is a condition of enormous clinical and economic importance and identification of associated or causative renal-failure genes would form a genetic basis for the detection of high-risk individuals and assist in development of intervention and treatment strategies to prevent this condition. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension, Kidney Failure, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse

Study Overview
=================
Brief Summary
-----------------
Sixty patients were randomized to receive either placebo or diazepam in addition to mechanical physiotherapy and analgesics for the first 7 days of conservative treatment of clinically and radiologically confirmed lumbar disk prolapse

Official Title
-----------------
Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse: a Prospective Randomized Clinical Trial

Conditions
-----------------
Pain, Disability, Paresis

Intervention / Treatment
-----------------
* Drug: benzodiacepine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sciatica without or with neurological deficit attributable to lumbar disc prolapse CT or MRI confirmation of lumbar disc prolapse informed consent Exclusion Criteria: bladder or bowel disturbance acute (< 24 h) development of paresis grade 1 or plegia taken benzodiazepines for more than 2 weeks history of benzodiazepine intolerance prior surgery for disc prolapse, or prior trauma to the vertrebral column

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br>placebo (2 tablets daily) | Drug: benzodiacepine<br>* diazepam (2 x 5 mg/ die)<br>|
| Experimental: B<br>diazepam (2 x 5 mg) | Drug: benzodiacepine<br>* diazepam (2 x 5 mg/ die)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| (i) median extent of reduction of referred pain |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| median duration of inability to work after discharge |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physiotherapy, Tuebingen concept, benzodiazepines, muscle relaxants, disc herniation
HCV Care Pathway in Ile-de-France

Study Overview
=================
Brief Summary
-----------------
The main objective of this research is to evaluate a care pathway adapted to different category populations at risk of being infected with the hepatitis C virus in order to improve both the diagnosis turnaround times and the access to treatment. The aim is to allow a quick and effective access to diagnosis and treatment of HCV by strengthening the city hospital networks, access to early consultations and coordination of medical social actors.

Detailed Description
-----------------
The current estimation of infected persons with chronic hepatitis C in France is over 200 ,000. It appears that prevention, screening, care management, medical and social care of patients can be significantly improved especially among the most vulnerable populations. Indeed, these new HCV infections are mediated by drug-using people, prisoners, migrants, men who have sex with men (MSM) and who are supported too late and without real access to treatment.

Official Title
-----------------
HCV Care Pathway in Ile-de-France

Conditions
-----------------
Hepatitis C Virus

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old and more Positive Hepatitis C virus Patient having expressed a non-objection to participate in this research Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Population at Risk<br>Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures. | Other: No intervention<br> <br> |
| Prison population<br>Proposal of participation to a  consultation arrivants  by the staff of medical units correctional | Other: No intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients effectively cared divided by number of patients eligible to care. |  | Year 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients cared in the HCV care pathway in Ile-de-France |  | Year 3 | 
| Number of patients effectively treated divided by number of patients eligible to DAA treatment. |  | Year 3 | 
| Delay between HCV diagnosis and early consultation |  | Year 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
care pathway, hospital- private network, early consultation
Post Extubation Chest Physiotherapy in ICU

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the efficacy of chest physiotheray treatment in preventing pulmonary complications and weaning faliure, in extubated critically ill patients.

Official Title
-----------------
The Effect of Post Extubation Chest Physiotherapy on Respiratory Complications and Weaning Failure in Critically Ill Patients

Conditions
-----------------
Weaning From Mechanical Ventilation

Intervention / Treatment
-----------------
* Other: chest physiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:ICU patients, over 18 years' old, mechanical ventilated over 24 hours, candidates for extubation - Exclusion Criteria: Mental conditions, retardation, dementia, pregnancy, re-intubated patients -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: chest physiotherapy<br>chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more. | Other: chest physiotherapy<br>* chest physiotherapy, up to one hour from extubation, in ICU patients<br>|
| No Intervention: control group<br>This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| re-intubation | re-intubation up to 48 hours post extubation will be considered a weaning failure | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxygen saturation decrease |  | 48 hours |
Hyaluronic Acid, Corticosteroid and Electrotherapy in Subacromial Impingement Syndrome

Study Overview
=================
Brief Summary
-----------------
Background: Electrotherapy, corticosteroid, and hyaluronic acid have been used to treat subacromial impingement syndrome. However, we need to compare treatment options to provide the optimal results. This study aims to compare the effect of hyaluronic acid, corticosteroid, and electrotherapy in subacromial impingement syndrome. Design: Ninety five patients were randomised into three equal groups according to treatment types. Hyaluronic acid (20 mg/2ml, three times one week apart) or corticosteroid (triamcinolone acetonide, 40 mg/ml, single dose) treatments were applied as subacromial injections. Electrotherapy consisted of 14 sessions TENS (20 min.), hotpack (20 min.) and ultrasound (1.5watt/cm2, 1 MHz, 6 min.). Patients were evaluated before treatment, one and four weeks post end of treatment. Visual Analogue Scale (VAS), range of motion (ROM), and Shoulder Disability Questionnaire (SDQ) were used as outcome measures.

Official Title
-----------------
Subakromiyal sıkışma Sendromunda Hyaluronik Asit, Kortikosteroid ve Elektroterapi

Conditions
-----------------
Subacromial Impingement, Pain, Shoulder

Intervention / Treatment
-----------------
* Drug: Hyaluronic acid
* Drug: Corticosteroids Triamcinolone Acetonide
* Other: Electrotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The diagnosis of subacromial impingement syndrome Exclusion Criteria: Patients aged <20 or >50 years or who have the following medical conditions were excluded: physical therapy or injection in the past 6 months, shoulder instability, acute trauma, adhesive capsulitis, psychiatric illness, diabetes mellitus, malignancy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Electrotherapy<br> | Other: Electrotherapy<br>* electrotherapy<br>|
| Active Comparator: corticosteroid<br> | Drug: Corticosteroids Triamcinolone Acetonide<br>* triamcinolone acetonide, 40 mg/ml, single dose<br>|
| Active Comparator: hyaluronic acid<br> | Drug: Hyaluronic acid<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale | Higher scores represent higher level of shoulder pain. | 1 min. | 
| range of motion | Higher scores represent lower level of shoulder function. | 5 min. | 
| Shoulder Disability Questionnaire | Higher scores represent higher level of shoulder pain. | 15 min |
Beginnings Study Follow up

Study Overview
=================
Brief Summary
-----------------
This study will help us learn more about how early infant diet may influence child's growth and development at age 14.

Detailed Description
-----------------
This study is to follow the infants that were enrolled in Beginnings study which purpose was to characterize physical growth, body composition, dietary intake, neurobehavioral development, and brain function of infants and children fed mostly breast milk, milk based formula, or soy based formula during their first year of life up to age 6. This study will call back those children when they turn 14 to compare growth, sexual maturation, and development between the three diets.

Official Title
-----------------
Beginnings Study Follow up

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Beginnings study former participants Exclusion Criteria: Dropped participants for medical diagnosis or medical conditions

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast milk fed<br>Fed primarily breast fed as an infant | |
| Milk based formula fed<br>Fed primarily milk based formula as an infant | |
| Soy based formula fed<br>Fed primarily soy based formula as an infant | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth and development | Will be determined with body composition equipment | 14 years |
Corneal Topographer Fluorescein Patterns

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine if corneal topography can be used to predict the fluorescein pattern of keratoconus lenses on the eye. A corneal topography image will be taken and the computer selected lens will be placed on the eye. After placement of the lens color photographs will be taken of the eye's fluorescein pattern and compared to the computer predicted pattern.

Detailed Description
-----------------
Subject population: keratoconus patients who have not undergone corneal surgery 100 subjects who come to UIHC for their contact lens care. We will approach them at their visit. We will not call potential participants from a database. If topography is impossible to capture. Concommitant Corneal Disease Minors will be excluded

Official Title
-----------------
Objective and Subjective Correlation Between Clinical Fluorescein Patterns and Theoretical Patterns Using the Medmont Corneal Topographer

Conditions
-----------------
Keratoconus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 yrs of age or older with diagnosis of keratoconus and contact lens wearer Exclusion Criteria: Noncommittant corneal disease or surgery Inability to capture topography measurement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Corneal Topographer Fluorescein Patterns<br>Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns | Comparison of fluorescein patterns of rgp contact lens. Bearing and elevation fluorescein patterns will be compared between the actual (photo) and theoretical (computer generated) fluorescein patterns using standard clinical means. | Baseline first visit |